PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brheartjLink to Publisher's site
 
Br Heart J. 1980 September; 44(3): 290–296.
PMCID: PMC482400

Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.

Abstract

The effect of the converting enzyme inhibitor captopril on arterial pressure, the components of the renin-angiotensin-aldosterone system, and body sodium and potassium content was studied in eight hypertensive patients with renal artery stenosis and, in conjunction with diuretics, in seven patients with hypertension unresponsive to previous treatment. Two hours after the first dose, captopril caused significant falls in systolic and diastolic pressures, plasma angiotensin II, and aldosterone, with converse increases in angiotensin I and both active and total renin; the initial fall in diastolic pressure was significantly related to the drop in plasma angiotensin II. The biochemical changes were sustained during prolonged treatment, even when diuretics were added. One untreated patient with renal artery occlusion had severe secondary aldosterone excess, was sodium and potassium depleted, and severely hyponatraemic and hypokalaemic; captopril restored blood pressure, plasma electrolyte concentrations, and exchangeable sodium and total body potassium to normal. In one man with renal artery stenosis and overall renal impairment captopril led to sodium retention, and blood pressure did not fall until a diuretic was added. In the remaining patients with renal artery stenosis, pretreatment renin, angio tensin II, and aldosterone concentrations were either normal or only modestly raised, and plasma electrolyte concentrations and body content of sodium and potassium were normal. Captopril alone controlled arterial pressure in all, three cases showing a gradual fall of pressure over the first six weeks of treatment; no significant changes in exchangeable sodium or total body potassium were seen. The group of patients with previously intractable hypertension were all controlled with a combination of captopril and diuretic.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1006K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Atkinson AB, Robertson JI. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836–839. [PubMed]
  • Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, McKinstry DN, Gavras I. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979 Jan;90(1):19–23. [PubMed]
  • Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis. Hypertension. 1979 May-Jun;1(3):274–280. [PubMed]
  • Brunner HR, Waeber B, Wauters JP, Turin G, McKinstry D, Gavras H. Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet. 1978 Sep 30;2(8092 Pt 1):704–707. [PubMed]
  • Bravo EL, Tarazi RC. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979 Jan-Feb;1(1):39–46. [PubMed]
  • Johnston CI, Millar JA, McGrath BP, Matthews PG. Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. Lancet. 1979 Sep 8;2(8141):493–496. [PubMed]
  • Atkinson AB, Davies DL, Leckie B, Morton JJ, Brown JJ, Fraser R, Lever AF, Robertson JI. Hyponatraemic hypertensive syndrome with renal-artery occlusion corrected by captopril. Lancet. 1979 Sep 22;2(8143):606–609. [PubMed]
  • Atkinson AB, Brown JJ, Fraser R, Leckie B, Lever AF, Morton JJ, Robertson JI. Captopril in hypertension with renal artery stenosis and in intractable hypertension; acute and chronic changes in circulating concentrations of renin, angiotensins I and II and aldosterone, and in body composition. Clin Sci (Lond) 1979 Dec;57 (Suppl 5):139s–143s. [PubMed]
  • BROWN JJ, PEART WS, OWEN K, ROBERTSON JI, SUTTON D. The diagnosis and treatment of renal-artery stenosis. Br Med J. 1960 Jul 30;2(5195):327–338. [PMC free article] [PubMed]
  • Semple PF, Cumming AM, Millar JA. Angiotensins I and II in renal vein blood. Kidney Int. 1979 Mar;15(3):276–282. [PubMed]
  • Davies DL, Robertson JW. Simultaneous measurement of total exchangeable potassium and sodium using 43 K and 24 Na. Metabolism. 1973 Feb;22(2):133–137. [PubMed]
  • Boddy K, King PC, Tothill P, Strong JA. Measurement of total body potassium with a shadow shield whole-body counter: calibration and errors. Phys Med Biol. 1971 Apr;16(2):275–282. [PubMed]
  • Boddy K, Brown JJ, Davies DL, Elliott A, Harvey I, Haywood JK, Holloway I, Lever AF, Robertson JI, Williams ED. Concurrent estimation of total body and exchangeable body sodium in hypertension. Clin Sci Mol Med. 1978 Feb;54(2):187–191. [PubMed]
  • Davies DL, Beevers DG, Briggs JD, Medina AM, Robertson JI, Schalekamp MA, Brown JJ, Lever AF, Morton JJ, Tree M. Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. Lancet. 1973 Mar 31;1(7805):683–686. [PubMed]
  • Schalekamp MA, Beevers DG, Briggs JD, Brown JJ, Davies DL, Fraser R, Lebel M, Lever AF, Medina A, Morton JJ, et al. Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system. Am J Med. 1973 Sep;55(3):379–390. [PubMed]
  • BAUER H, FORBES L. Unilateral renal artery obstruction associated with malignant nephrosclerosis confined to the opposite kidney. Am Heart J. 1952 Oct;44(4):634–638. [PubMed]
  • Brown JJ, Lever AF, Davies DL, Robertson JI. Renin and angiotensin. A survey of some aspects. Postgrad Med J. 1966 Mar;42(485):153–176. [PMC free article] [PubMed]
  • Barraclough MA. Sodium and water depletion with acute malignant hypertension. Am J Med. 1966 Feb;40(2):265–272. [PubMed]
  • Atkinson AB, Brown JJ, Fraser R, Leckie B, Lever AF, Morton JJ, Robertson JI. Captopril, angiotensin II, and sodium in blood-pressure regulation. Lancet. 1979 May 26;1(8126):1140–1140. [PubMed]
  • Marks ES, Bing RF, Thurston H, Swales JD. Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat. Clin Sci (Lond) 1980 Jan;58(1):1–6. [PubMed]
  • Riegger AJ, Lever AF, Millar JA, Morton JJ, Slack B. Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors. Lancet. 1977 Dec 24;2(8052-8053):1317–1319. [PubMed]
  • Atkinson AB, Brown JJ, Fraser R, Lever AF, Morton JJ, Riegger AJ, Robertson JI. Angiotensin II and renal hypertension in dog, rat and man: effect of converting enzyme inhibition. Clin Exp Hypertens. 1980;2(3-4):499–524. [PubMed]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group